- Home
- SANG vs ABOS Comparison
SANG vs ABOS Comparison
Compare SANG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- ABOS
- Stock Information
- Founded
- SANG 1984
- ABOS 1996
- Country
- SANG Canada
- ABOS United States
- Employees
- SANG N/A
- ABOS N/A
- Industry
- SANG Computer Software: Programming Data Processing
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- ABOS Health Care
- Exchange
- SANG Nasdaq
- ABOS Nasdaq
- Market Cap
- SANG 189.6M
- ABOS 72.7M
- IPO Year
- SANG 2021
- ABOS 2021
- Fundamental
- Price
- SANG $6.42
- ABOS $1.18
- Analyst Decision
- SANG
- ABOS Strong Buy
- Analyst Count
- SANG 0
- ABOS 4
- Target Price
- SANG N/A
- ABOS $6.50
- AVG Volume (30 Days)
- SANG 1.9K
- ABOS 570.9K
- Earning Date
- SANG 05-08-2025
- ABOS 08-12-2025
- Dividend Yield
- SANG N/A
- ABOS N/A
- EPS Growth
- SANG N/A
- ABOS N/A
- EPS
- SANG N/A
- ABOS N/A
- Revenue
- SANG $238,264,000.00
- ABOS N/A
- Revenue This Year
- SANG N/A
- ABOS N/A
- Revenue Next Year
- SANG $2.91
- ABOS N/A
- P/E Ratio
- SANG N/A
- ABOS N/A
- Revenue Growth
- SANG N/A
- ABOS N/A
- 52 Week Low
- SANG $4.08
- ABOS $0.86
- 52 Week High
- SANG $7.99
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- SANG 60.10
- ABOS 50.62
- Support Level
- SANG $5.90
- ABOS $1.12
- Resistance Level
- SANG $6.37
- ABOS $1.26
- Average True Range (ATR)
- SANG 0.10
- ABOS 0.07
- MACD
- SANG 0.02
- ABOS -0.01
- Stochastic Oscillator
- SANG 54.88
- ABOS 37.46
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.